Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Metastatic Distal Bile Duct Adenocarcinoma
- Metastatic Gallbladder Carcinoma
- Metastatic Intrahepatic Cholangiocarcinoma
- Recurrent Distal Bile Duct Adenocarcinoma
- Recurrent Gallbladder Carcinoma
- Recurrent Intrahepatic Cholangiocarcinoma
- Stage IV Distal Bile Duct Cancer AJCC v8
- Stage IV Gallbladder Cancer AJCC v8
- Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Unresectable Liver Carcinoma
Interventions
- BIOLOGICAL: Atezolizumab
- PROCEDURE: Biopsy
- PROCEDURE: Biospecimen Collection
- DRUG: Cobimetinib
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
- DRUG: Varlilumab
Sponsor
National Cancer Institute (NCI)